Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 1,068,991 shares, an increase of 173.2% from the May 14th total of 391,277 shares. Based on an average trading volume of 110,754,674 shares, the short-interest ratio is presently 0.0 days. Approximately 44.8% of the shares of the company are short sold.
Virax Biolabs Group Stock Performance
Shares of VRAX traded up $0.00 during mid-day trading on Friday, reaching $0.18. 728,684 shares of the company’s stock traded hands, compared to its average volume of 53,200,672. The business’s 50-day moving average price is $0.18 and its 200-day moving average price is $0.26. Virax Biolabs Group has a 12 month low of $0.10 and a 12 month high of $1.14.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Virax Biolabs Group presently has an average rating of “Hold” and a consensus target price of $1.00.
About Virax Biolabs Group
Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.
At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.
Recommended Stories
- Five stocks we like better than Virax Biolabs Group
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.
